Parkin Stabilizes Microtubules through Strong Binding Mediated by Three Independent Domains*

Fang Yang‡, Qian Jiang‡, Jinghui Zhao‡, Yong Ren‡, Mark D. Sutton§, and Jian Feng‡¶

From the ‡Department of Physiology and Biophysics and the §Department of Biochemistry, State University of New York at Buffalo, Buffalo, New York 14214

Received for publication, January 24, 2005, and in revised form, February 16, 2005
Published, JBC Papers in Press, February 28, 2005, DOI 10.1074/jbc.M500843200

Mutations of parkin, a protein-ubiquitin isopeptide ligase (E3), appear to be the most frequent cause of familial Parkinson's disease (PD). Our previous studies have demonstrated that parkin binds strongly to αβ tubulin heterodimers and microtubules. Here we show that the strong binding between parkin and tubulin, as well as between parkin and microtubules, was mediated by three independent domains: linker, RING1, and RING2. These redundant strong interactions made it virtually impossible to separate parkin from microtubules by high concentrations of salt (3.8 M) or urea (0.5 M). Parkin co-purified with tubulin and was found in highly purified tubulin preparation. Expression of either full-length parkin or any of its three microtubule-binding domains significantly attenuated colchicine-induced microtubule depolymerization. The abilities of parkin to bind to and stabilize microtubules were not affected by PD-linked mutations that abrogate its E3 ligase activity. Thus, the tubulin/microtubule-binding activity of parkin and its E3 ligase activity are independent. The strong binding between parkin and tubulin/microtubules through three redundant interaction domains may not only stabilize microtubules but also guarantee the anchorage of this E3 ligase on microtubules. Because many misfolded proteins are transported on microtubules, the localization of parkin on microtubules may provide an important environment for its E3 ligase activity toward misfolded substrates.

Parkinson’s disease (PD)1 is the most prevalent neurodegenerative movement disorder, affecting about 1–2% of people over 60 years of age (1). Although the pathogenesis of PD remains elusive, a complex interaction between environmental and genetic factors may underlie most sporadic cases (2). Among the PD-linked genes identified so far, parkin is the most prevalent genetic factor causing familial Parkinson’s disease; its mutations account for up to 50% of recessive PD cases (3, 4). As a protein-ubiquitin E3 ligase, parkin plays an important role in the ubiquitination and degradation of many substrates (5), such as CDCrel-1 (6), Pael Receptor (7), an O-glycosylated α-synuclein (8), synphilin-1 (9), cyclin E (10), αβ tubulin (11), and dopamine transporter (12).

Our previous studies have shown that parkin binds to microtubules and αβ tubulin heterodimers with very high affinity (11). The involvement of tubulin and microtubules in PD has been implicated in many previous reports. Tubulin is a major component of Lewy bodies (13), which are intracytoplasmic inclusions enriched in ubiquitinated proteins (14). It suggests that ubiquitinated tubulin may be present in Lewy bodies. Consistent with this, parkin, ubiquitinated proteins, and acetylated α-tubulin are accumulated in the aggresome in a microtubule-dependent manner when protein degradation through the 26 S proteasome is inhibited (15, 16). On the other hand, 1-methyl-4-phenylpyridinium (MPP+) and rotenone, two neurotoxins known to cause PD-like symptoms in animal models, potently depolymerize microtubules (17–20). Microtubule depolymerization induces tubulin degradation at both protein (21) and RNA levels (22). Because parkin is an E3 ligase of tubulin (11), its ability to ubiquitinate tubulin dissociated from microtubules by these PD toxins may at least be partly responsible for this rapid degradation of tubulin. Parkin exhibits a punctate subcellular localization along microtubules in a variety of cells, including neurons (11). Apart from its E3 ligase activity on tubulin, the strong binding between parkin and microtubules may anchor this E3 ligase on microtubules to serve its functions, as misfolded proteins are known to be transported along microtubules to the aggresome (23).

To understand the molecular determinants of the strong interaction between parkin and tubulin/microtubules, we mapped the domains of parkin that were responsible for this tight binding. Of the five functional domains of parkin, Linker, RING1, or RING2 were able to bind to tubulin and microtubules with high affinity, whereas the ubiquitin-like (Ubl) domain or In-between RING finger (IBR) domain did not have such abilities. Thus, three domains of parkin independently provided tight binding to tubulin and microtubules. Such strong, redundant interactions rendered it almost impossible to separate parkin from microtubules and tubulin. Parkin remained bound to microtubules in the presence of 3.8 M NaCl or 0.5 M urea. It always co-purified with tubulin on ion exchange or gel filtration chromatography and was found in highly purified tubulin preparation (>99% purity).

Expression of the domains that bound to tubulin and microtubules significantly reduced colchicine-induced microtubule depolymerization, suggesting that parkin may stabilize the microtubule network. We also found that PD-linked mutations of parkin (K161N, T240R, and C431F) did not significantly impair the binding of parkin with tubulin heterodimers or microtubules, nor did they affect the ability of parkin to stabilize microtubules against colchicine-induced depolymerization.

* This work was supported by National Institutes of Health Grant NS41722 (to J. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡ To whom correspondence should be addressed: Dept. of Physiology and Biophysics, State University of New York at Buffalo, Buffalo, NY 14214. Tel.: 716-829-2345; Fax: 716-829-2699; E-mail: jianfeng@buffalo.edu.

§ To whom correspondence should be addressed: Dept. of Biochemistry, State University of New York at Buffalo, Buffalo, NY 14214. Tel.: 716-829-2345; Fax: 716-829-2699; E-mail: jianfeng@buffalo.edu.

1 The abbreviations used are: PD, Parkinson’s disease; DA, dopamine; ER, endoplasmic reticulum; Ubl, ubiquitin-like; RING, really interesting new gene; IBR, in-between RING; MES, N-morpholinoethanesulfonic acid; E3, ubiquitin-protein isopeptide ligase; MPP+, 1-methyl-4-phenylpyridinium; CMV, cytomegalovirus; PIPES, 1,4-piperazine-diethanesulfonic acid; MAP, microtubule-associated protein.
Thus, the strong binding of parkin to microtubules may stabilize the microtubule network and anchor this E3 ligase to effectively ubiquitinate misfolded proteins being transported along microtubules.

**EXPERIMENTAL PROCEDURES**

**Antibodies and cDNAs**—A polyclonal antibody against parkin was generated previously. It recognizes only the correct band on Western blots (11). Monoclonal antibodies against α-tubulin (DM1A) and FLAG (M2) were purchased from Sigma. Polyclonal FLAG antibody used in the immunocytochemistry was purchased from Cayman Chemical (Ann Arbor, MI). Rhodamine- or fluorescein isothiocyanate-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Human parkin cDNA was amplified by reverse transcription PCR from SH-SYSY cells and was completely sequenced to ensure that no mistake was introduced by PCR. It was subcloned into pcMV-Tag2B (Stratagene, La Jolla, CA), which added a FLAG tag at the N terminus of the protein produced. Point mutants of parkin were generated by site-directed mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA). The mutant constructs were confirmed by DNA sequencing. cDNAs for different domains of parkin were obtained by PCR reactions using the full-length human parkin construct as the template. The cDNA sequences encoding amino acids 1–66 (linker), 237–253 (Linker), 217–310 (RING1 or R1), 395–465 (RING2 or R2), 1–237 (Ub-Linker), 307–465 (IRB-R2), and 217–465 (RIR) of parkin were cloned into pcMV-Tag2B vector between BamHI and SalI sites to generate FLAG-tagged constructs. The cDNA sequences encoding amino acids 307–405 (In-between RING, IRR) and 50 mM NaF, 5 mM EDTA, and 0.1 mM Na3VO4) for 20 min. Lysates were blotted with anti-FLAG or anti-HA to assess expression levels of transfected constructs. Expression levels of these FLAG-tagged constructs in pcDNA3.1 vector were higher than in pcMV-Tag2B vector and were thus used in all experiments. All constructs in the pcDNA3.1 vector were verified by sequencing.

**Cell Culture, Transfection, Immunoprecipitation, and Western Blot—** HEK293T cell line was cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% bovine fetal calf serum and antibiotics. Transient transfections of various constructs were performed by the calcium phosphate method (12). Thirty hours after transfection, cells cultured in 10-cm dishes were lysed on ice in cold lysis buffer (1% Triton X-100, 10 mM Tris, pH 7.6, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM EDTA, and 0.1 mM Na3VO4) for 20 min. Lysates were centrifuged at 16,000 × g for 10 min at 4 °C, and the supernatant was incubated at 37 °C and resuspended in PEM buffer at 4 °C to depolymerize microtubules. Equal amount of total proteins (10 μg for parkin blot and 2 μg for tubulin blot) from each fraction were boiled and separated by SDS-PAGE and analyzed by Western blotting with antibodies against FLAG, parkin, or α-tubulin, respectively.

**Chromatographic Purification of Parkin-tubulin Complex**—The microtubule-parkin pellet after elution with 2 M NaCl was rinsed and resuspended in PEM buffer without GTP (without taxol or GTP) at 37 °C and resuspended in PEM buffer at 4 °C to depolymerize microtubules. Equal amount of total proteins (10 μg for parkin blot and 2 μg for tubulin blot) from each fraction were boiled and separated by SDS-PAGE and analyzed by Western blotting with antibodies against FLAG, parkin, or α-tubulin, respectively.

**Immunocytochemistry**—COS-7 cells were cultured in Dulbecco’s modified Eagle’s medium with 10% bovine fetal calf serum and antibiotics. Transient transfections of various constructs were performed by using FuGENE 6 (Roche Applied Science) according to the manufacturer’s protocol. Sixteen hours after transfection, cells were fixed and co-stained with anti-FLAG (rabbit polyclonal) and anti-α-tubulin (mouse monoclonal) in methods used previously (11). Images were acquired under a 60× lenses of a Nikon fluorescence microscope with a charge-coupled device camera (Diagnostic Instrument, Sterling Heights, MI) and merged using the SPOT software (Diagnostic Instrument). For quantification of microtubule-containing (MT+) cells, at least 200 transfected cells or 500 untransfected cells from four coverslips were counted in separate experiments. The percentage of cells with at least one visible microtubule was calculated for each condition.

**Measurement of Free Tubulin in the Cell**—Free tubulin was extracted essentially as described previously (24). Briefly, HEK293T cells transfected or with various constructs were treated without or with 1 μM colchicine (1 μM) for 40 min at 37 °C in culture media. Cells were washed twice at 37 °C with 1 ml of Buffer A containing 0.1 M MES (pH 6.75), 1 mM MgSO4, 2 mM EDTA, 0.1 mM EGTA, and 4 mM glycerol. After the cultures were incubated at 37 °C for 5 min in free tubulin extraction buffer (Buffer A plus 0.1% Triton X-100 and protease inhibitors), the extracts were centrifuged at 37 °C for 2 min at 16,000 × g. The supernatant fractions containing free tubulin extracted from the cytosol. Equal amount of total proteins from the supernatant fractions were analyzed by Western blotting with anti-α-tubulin (Sigma). The intensity of tubulin bands was quantified from three different experiments with the software NIH imaging. Total cell lysates in a lysis buffer (1% Triton X-100, 10 mM Tris, pH 7.6, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM EDTA, and 0.1 mM Na3VO4) were boiled with anti-FLAG or anti-HA to assess expression levels of transfected constructs.

**RESULTS**

**Three Domains of Parkin Independently Bind to α/β-Tubulin Heterodimers**—To understand the molecular determinants for the strong interaction between parkin and tubulin (11), we generated a series of constructs expressing various domains of parkin to identify the tubulin-binding region(s). All of these constructs (Fig. 1A) were tagged with FLAG at the N terminus and could be efficiently expressed in HEK293T cells, except for the RING1 domain, whose expression level was much lower than that of the others (Fig. 1, B and C).

We first examined the ability of each individual domain of parkin to co-immunoprecipitate endogenous α/β-tubulin. HEK293 cells transfected without or with these domains or empty vector were lysed at 4 °C in a buffer containing 1%
obtained when we perform the same experiments in the presence of 25 μM colchicine (data not shown). This is consistent with our previous result that the binding between parkin and tubulin α/β heterodimer is not affected by colchicine (11) and suggests that each of the three domains (Linker, RING1, and RING2) binds to tubulin heterodimer at 4 °C. Although the RING1 domain was expressed at a much lower level, its ability to co-immunoprecipitate with tubulin was commensurate with its expression.

To confirm these observations, we expressed combinations of various parkin domains in HEK293T cells and performed the same co-immunoprecipitation assays with anti-α-tubulin. As shown in Fig. 1C, the UL constructs, which covered Ubl and Linker domains, was strongly co-immunoprecipitated with tubulin. So were the RIR (RING1-IBR-RING2), RI (RING1-IBR), or IR (IBR-RING2) constructs. As long as a construct included one of the tubulin-binding domains (Linker, RING1, or RING2), it exhibited strong co-immunoprecipitation with α/β-tubulin. Thus, the Ubl or IEB domain did not interfere with the tubulin-binding activity of Linker, RING1, or RING2.

The Three Tubulin-binding Domains of Parkin Also Strongly Associate with Microtubules—Because our previous study has shown the strong binding between parkin and microtubules in taxol-mediate microtubule co-assembly assays (11), we wondered whether the interaction was mediated by the three tubulin-binding domains of parkin. To test this, we combined lysates of HEK293T cells expressing individual parkin domains with rat brain homogenates, which were used as a rich source of tubulin. After ultracentrifugation of the mixed lysates at 4 °C, the supernatant fraction was used in taxol-mediated microtubule co-assembly experiments. The pellet fraction after two cycles of co-assembly (P2) was incubated in MAP dissociation buffer containing 2 M NaCl to assess the binding affinity between parkin domains and microtubules.

As shown in Fig. 2, α-tubulin was highly enriched in the pellet fractions containing microtubules (P1, P2, and P3), compared with the soluble fractions (S1, S2, and S3). Consistent with our previous result, endogenous parkin from rat brain (and negligible amount of endogenous parkin from HEK293T cells) was found exclusively in the pellet fractions (11). Under the same condition, we found that Linker or RING1 (R1) domain was always in the pellet fraction with microtubules, even in the presence of 2 M NaCl. The RING2 (R2) domain exhibited partial co-assembly with microtubules. In contrast, the Ubl or IEB domain was in the S1 fraction, unable to co-assemble with microtubules. We also tested constructs that expressed combinations of various parkin domains. IRB-RE, Ubl-Linker, or R1-IBR was able to strongly co-assemble with microtubules. Thus, as long as the combined construct contained one of the tubulin-binding domains (Linker, R1, or R2), it co-assembled with microtubules. Because IRB itself did not co-assemble with microtubules at all, the ability of IRB-R2 to bind to microtubules most likely comes from R2. It seems that there might be some structural hindrance that affects the efficient binding of R2 with microtubules, which appears to be removed when R2 is in the context of IRB-R2, as in the native sequence of parkin. Together, these results suggest that the three tubulin-binding domains of parkin also mediate its strong association with microtubules.

Parkin Cannot Be Dissociated from Microtubules with High Concentrations of NaCl or Urea—To assess the affinity between parkin and microtubules, we performed the taxol-mediated microtubule co-assembly assay and incubated microtubules in the P2 pellet in MAP dissociation buffer (PEM buffer plus GTP, but no taxol) containing 2 or 3.8 M of NaCl for 45 min at 37 °C. After centrifugation, the supernatant and pellet fractions were designated as S3 and P3 (for 2 M NaCl wash) and S4 and P4 (for 3.8 M NaCl wash), respectively. As shown in Fig. 3A,
parkin still remained in the pellet fraction with microtubules even in the presence of 3.8 mM NaCl.

To separate parkin from microtubules, we resorted to urea. After centrifugation, supernatant and pellet fractions each cycle were designated as S1, P1, S2, P2, S3, and P3, respectively. Equal amounts of total proteins from each fraction (2 μg for α-tubulin blot, 10 μg for the rest) were analyzed by Western blotting with antibodies against α-tubulin, parkin, or FLAG. Endogenous parkin and tubulin were always in microtubule fraction in the pellet. Exogenously expressed Linker, R1, IBR-R2, Ubl-Linker, and R1-IBR constructs strongly co-assembled with microtubules, whereas the R2 domain co-assembled with microtubules to a lesser degree. Ubl or IBR domains did not co-assemble with microtubules. All experiments were repeated at least three times with similar results.

Co-purification of Parkin and α/β-Tubulin—Having failed to separate parkin from microtubules, we tried to isolate parkin from tubulin. As parkin was highly enriched in the microtube pellet after 2 mM NaCl wash (P3), we used this preparation from rat brains as the starting material to purify parkin by ion-exchange and gel-filtration chromatographies. Western blotting of equal amounts of total proteins from each fraction (2 μg for tubulin blot and 10 μg for parkin blot) showed that parkin remained in the pellet fraction with microtubules even in the presence of 3.8 mM NaCl. B, the pellet fraction P3 was resuspended and separated into five equal parts, each incubated at 37 °C for 45 min in PEM buffer containing 0.5, 1, 1.5, 2, or 4 mM urea, respectively. Western blotting of equal amounts of total proteins from each fraction (2 μg for tubulin blot and 10 μg for parkin blot) showed that parkin was eluted from the pellet into the supernatant fraction with urea at or above 1 mM. C, microtubules in the pellet fraction P3 from A were dialyzed overnight at 4 °C against ion exchange purification buffer (10 mM NaCl, 20 mM sodium phosphate, 1 mM dithiothreitol, 1 mM EDTA, pH 7.5) and centrifuged to obtain clear supernatant, which were separated by ion exchange chromatography with a NaCl gradient from 10 mM to 1 M at 4 °C. Western blotting of equal fractions of the eluted samples with antibodies against parkin or α-tubulin showed that parkin copurified with tubulin. D, purified tubulin (>99% purity) from a commercial source (Cytoskeleton, Inc., Denver, CO) was analyzed by Western blotting with antibodies against α-tubulin, β-tubulin, or parkin, respectively. The amounts of total protein loaded on the gel were 0.1, 0.1, or 1 μg for each blot, respectively. Parkin was detected in purified tubulin. All experiments were repeated for at least three times with similar results.

Co-purification of Parkin and α/β-Tubulin—Having failed to separate parkin from microtubules, we tried to isolate parkin from tubulin. As parkin was highly enriched in the microtube pellet after 2 mM NaCl wash (P3), we used this preparation from rat brains as the starting material to purify parkin by ion-exchange and gel-filtration chromatographies. Western blotting of equal amounts of total proteins from each fraction (2 μg for tubulin blot and 10 μg for parkin blot) showed that parkin remained in the pellet fraction with microtubules even in the presence of 3.8 mM NaCl. B, the pellet fraction P3 was resuspended and separated into five equal parts, each incubated at 37 °C for 45 min in PEM buffer containing 0.5, 1, 1.5, 2, or 4 mM urea, respectively. Western blotting of equal amounts of total proteins from each fraction (2 μg for tubulin blot and 10 μg for parkin blot) showed that parkin was eluted from the pellet into the supernatant fraction with urea at or above 1 mM. C, microtubules in the pellet fraction P3 from A were dialyzed overnight at 4 °C against ion exchange purification buffer (10 mM NaCl, 20 mM sodium phosphate, 1 mM dithiothreitol, 1 mM EDTA, pH 7.5) and centrifuged to obtain clear supernatant, which were separated by ion exchange chromatography with a NaCl gradient from 10 mM to 1 M at 4 °C. Western blotting of equal fractions of the eluted samples with antibodies against parkin or α-tubulin showed that parkin co-purified with tubulin. D, purified tubulin (>99% purity) from a commercial source (Cytoskeleton, Inc., Denver, CO) was analyzed by Western blotting with antibodies against α-tubulin, β-tubulin, or parkin, respectively. The amounts of total protein loaded on the gel were 0.1, 0.1, or 1 μg for each blot, respectively. Parkin was detected in purified tubulin. All experiments were repeated for at least three times with similar results.
sample buffer for ion-exchange chromatography, cleared supernetant, which was enriched for tubulin and parkin, was applied to a 1-ml Mono Q HR 5/5 ion-exchange chromatography column on a fast protein liquid chromatography system. Proteins were eluted with a linear NaCl gradient from 0.01 to 1 M. Western blotting of protein-containing fractions with antibodies against α-tubulin or parkin showed that parkin co-purified with tubulin (Fig. 3C). We also tried gel-filtration chromatography using either pooled fractions after ion-exchange chromatography purification or tubulin dissociated from P₂₁ microtubule pellet. Western blotting of fractions after gel-filtration chromatography showed that parkin was still in the same fractions as tubulin (data not shown). This led us to directly examine highly purified tubulin (>99% pure) from a commercial source (Cytoskeleton, Inc.) by Western blotting with anti-parkin. As shown in Fig. 3D, parkin was clearly seen in this purified tubulin preparation when we ran different amounts of tubulin (0.1 or 1 µg) side by side and blotted each lane separately with antibodies against α-tubulin, β-tubulin, or parkin, respectively. As the amount of parkin in this preparation appears to be much lower than those of tubulins, this minor “contaminant” is masked by the overabundance of tubulins, which migrate very closely to parkin on SDS-PAGE. These independent lines of evidence suggest that parkin cannot be easily separated from α/β-tubulin by conventional methods and may naturally exist in a complex with tubulin.

Parkin Attenuates Colchicine-induced Microtubule Depolymerization through Its Three Tubulin/Microtubule-binding Domains—The strong binding between parkin and microtubules suggests that parkin may stabilize microtubule networks in the cell. To test this, we transfected COS-7 cells with various FLAG-tagged parkin constructs and treated the cultures with the microtubule-depolymerizing agent colchicine (1 µM for 12 h). COS-7 cells were used because of their flat shape, which enabled easy observation of microtubules. Fixed cultures were co-stained with anti-FLAG (red) and anti-α-tubulin (green) to observe microtubules in transfected and untransfected cells. Although the rabbit polyclonal antibody against FLAG had some cross-reactivity with other cellular proteins in Western blotting and immunostaining (data not shown), it was sufficient to distinguish transfected and untransfected cells. As shown in Fig. 4, A and B, microtubules in untransfected COS-7 cells were totally depolymerized by the colchicine treatment. In contrast, expression of the full-length wild-type parkin significantly reduced colchicine-induced microtubule depolymerization (Fig. 4, C and D). Although expression of the Linker (Fig. 4, G and H), R1-IBR (Fig. 4, I and J), or R2 (Fig. 4, M and N) construct had an effect similar to that of the wild-type parkin, transfection of the Ubl (Fig. 4, E and F) or IBR (Fig. 4, K and L) domain had no such an effect. Because the expression level of the R1 construct was much lower than the other constructs (Fig. 1B), we observed very few cells that were visibly transfected with the R1 construct. Thus, we used the R1-IBR construct instead of the R1 construct. The R1-IBR construct behaved in the same way as the R1 domain and oppositely to the IBR domain in co-immunoprecipitation with tubulin (Fig. 1) and co-assembly with microtubules (Fig. 2). Consequently, it is reasonable to assume that the behavior of R1-IBR following colchicine treatment would represent R1, instead of IBR. Indeed, the effect of R1-IBR on colchicine-induced microtubule depolymerization was similar to other microtubule-binding domains and different to constructs that did not bind to microtubules (Fig. 4).

To quantify the effects of these constructs, we counted at least 200 transfected cells (for each condition in Fig. 4, C–N) or 500 untransfected cells (for each condition in Fig. 4, A and B) from four coverslips in separate experiments. The percentage of transfected cells with at least one obvious microtubule after colchicine treatment was calculated for each construct. As shown in Fig. 4O, 36.8 ± 1.8% of cells transfected with wild-type parkin still had at least one obvious microtubule after the colchicine treatment. It is significantly different from the situation in untransfected cells (2.7 ± 0.4%). The effects of Linker (32.8 ± 2.1%), R1-IBR (33.7 ± 2.7%), and R2 (31.4 ± 2.9%) were similar to that of the wild-type and significantly different from that of the untransfected (p < 0.001). In contrast, the effects of Ubl (17.6 ± 1.4%) and IBR (14.3 ± 0.8%) were significantly smaller than that of the wild-type (p < 0.001). We also transfected COS-7 cells with unrelated constructs (β3 or β2 subunits of Na⁺/K⁺-ATPase) to see whether the effect of Ubl or IBR was nonspecific. Expression of β3 (16.3 ± 0.9%) or β2 (data not shown), which has no known connections to microtubules, attenuated colchicine-induced microtubule depolymerization to a similar extent as that caused by Ubl or IBR (p > 0.05 among the three constructs). Thus, these relatively small effects appear to be nonspecific and are quite different from that of wild-type parkin.

To further substantiate our findings, we directly measured the amount of free tubulin in the cell by gently lysing the cells in a low concentration of detergent (0.1% Triton X-100) at 37 °C without disturbing polymerized tubulin in microtubules. The amount of tubulin in the extract represents tubulin originally existed as free a/β heterodimers in the cell (24). HEK293T cells transfected without or with various FLAG-tagged parkin constructs or HA-β3 were treated without or with 1 µM colchicine for 40 min. As expected, colchicine treatment greatly increased the amount of free tubulin in the cell by depolymerizing microtubules (Fig. 4P, upper panel, lanes 1 versus 2). Expression of wild-type parkin (WT), Linker, R1, R1-IBR, or R2 domain markedly attenuated colchicine-induced increase in the amount of free tubulin. In contrast, Ubl or IBR domain did not have such an effect and behaved just like untransfected or the control construct HA-β3 (Fig. 4P, upper panel). Quantification of results from three independent experiments showed that the amount of free tubulin after colchicine treatment in cells transfected with WT (157 ± 12% of untransfected, untreated controls, p < 0.001), Linker (209 ± 19%, p < 0.05), R1 (187 ± 11%, p < 0.01), R1-IBR (178 ± 11%, p < 0.01), or R2 (185 ± 9%, p < 0.01) was significantly less than that in untransfected cells (269 ± 12%). The effect of Ubl (274 ± 13%, p > 0.75), IBR (269 ± 13%, p > 0.95), or HA-β3 (272 ± 14%, p > 0.85) was not significantly different from that of untransfected (269 ± 12%). Thus, like the wild-type, any parkin construct containing one of its three tubulin/microtubule-binding domains greatly reduced colchicine-induced microtubule depolymerization. The two domains that did not bind to tubulin and microtubules (Ubl and IBR) also did not attenuate microtubule depolymerization induced by colchicine. The expression level of each FLAG-tagged parkin construct or HA-tagged β3 is shown in the lower panel of Fig. 4P. The β3 subunit of Na⁺/K⁺-ATPase is a heavily glycosylated transmembrane protein and migrates as multiple bands on SDS-PAGE.

Together, these morphological and biochemical results suggest that microtubule-binding domains of parkin, like the full-length, stabilize microtubule networks against colchicine-induced microtubule depolymerization. In contrast, parkin domains that did not bind to microtubules had no such an effect.

PD-linked Mutations of Parkin Do Not Disrupt the Binding between Parkin and α/β-Tubulin—To test whether the strong binding between parkin and tubulin is affected by mutations of parkin that cause Parkinson’s disease, we transfected FLAG-tagged wild-type parkin or its PD-linked mutants (K161N, T240R, or C431F) in HEK293T cells and examined the co-
immunoprecipitation of these parkin constructs with endogenous H9251/H9252-tubulin. As shown in the top panel of Fig. 5A, all three point mutants and wild-type parkin were found at comparable levels in H9251-tubulin immunoprecipitates, indicating that the binding between parkin and tubulin was not disrupted by any of the three PD-causing mutations. Western blotting of the total lysates showed that parkin and its mutants were expressed at similar levels (Fig. 5A, bottom panel).

Each of the three point mutations that we tested is in one of the tubulin-binding domains: K161N in the Linker, T240R in RING1, and C431F in RING2. As each mutation would only affect one tubulin-binding domain, the lack of difference between wild-type parkin and these point mutants could be simply due to the fact that the other two tubulin-binding domains can still compensate for the interaction. To test this, we introduced these point mutations to their corresponding tubulin-binding domains and examined whether the co-immunoprecipitation between these parkin domains and tubulin is affected or not. As shown in Fig. 5B, each of the three constructs L/K161N (Linker with K161N mutation), R1/T240R (RING1 with T240R mutation), and R2/C431F (RING2 with C431F mutation) was expressed in HEK293T cells and was found in H9251-tubulin immunoprecipitates. Thus, none of the three PD-linked mutations disrupted the binding between its corresponding domains and tubulin. Expression level of R1/T240R was much lower than the other two constructs (Fig. 5B). When we examined the expression levels of L versus L/K161N; R1 versus R1/T240R; and R2 versus R2/C431F side by side on the same gel, we found

Three Domains of Parkin Bind to and Stabilize Microtubules

Fig. 4. Expression of microtubule-binding domains of parkin attenuated colchicine-induced microtubule depolymerization. A–N, COS-7 cells were transfected with vector (A and B), wild-type parkin (C and D), Ubl domain (E and F), Linker domain (G and H), R1-IBR domain (I and J), IBR domain (K and L) or R2 domain (M and N), and treated with vehicle control (A, C, E, G, I, K, and M) or 1 μM colchicine (B, D, F, H, J, L, and N) for 12 h. All constructs were tagged with FLAG at the N terminus. Fixed cells were co-stained with antibodies against α-tubulin (green) and FLAG (red). Wild-type parkin or microtubule-binding domains of parkin (Linker, R1-IBR, and R1) reduced colchicine-induced microtubule depolymerization, whereas parkin domains that did not bind to microtubules (Ubl and IBR) did not have such effect. Bars, 10 μm. O, percentages of cells with at least one obvious microtubule after colchicine treatment were calculated for all the constructs used in A–N, as well as a control construct expressing the β3 subunit of Na+/K+-ATPase. At least 200 transfected cells (for each condition in C–N) and 500 untransfected cells (for A and B) were counted from four coverslips in separate experiments for each construct. *, p < 0.001 versus wild-type parkin. No significant differences were found between full-length parkin, Linker, R1-IBR, and R2 (p > 0.1). There were also no significant differences between Ubl, IBR, and β3 (p > 0.05). All the transfected cells showed significant difference compared with non-transfected cells (p < 0.001). P, HEK293T cells were transfected without or with various FLAG-tagged parkin constructs or HA-tagged β3 subunit of Na+/K+-ATPase and treated without or with colchicine (1 μM) for 40 min. Free tubulin was extracted from the cells and analyzed by Western blotting with anti-α-tubulin (upper panel). Expression of wild-type parkin and constructs containing at least one of its tubulin-binding domains significantly reduced colchicine-induced microtubule depolymerization. Total cell lysates were blotted with anti-FLAG or anti-HA to show expression levels of FLAG-tagged parkin constructs or HA-β3 (lower panel).
that the mutations did not significantly affect the expression of the corresponding parkin domains (data not shown).

**Co-assembly of PD-linked Parkin Mutants with Microtubules**—Because the three PD-linked mutations of parkin did not disrupt the binding between parkin and tubulin, we tested whether they affected the ability of parkin to co-assemble with microtubules. HEK293T cells transfected with Linker/K161N, R1/T240R, or R2/C431F were homogenized with rat brain microtubule co-assembly assays were performed in the same way as in Fig. 2. As shown in Fig. 6, endogenous parkin was always in the pellet fractions with microtubules, even in the presence of 2 M NaCl (S3 versus P3). Linker/K161N and R1/T240R strongly co-assembled with microtubules and could not be eluted from the microtubule pellet with 2 M NaCl (Fig. 6). In contrast, R2/C431F did not co-assemble with microtubules effectively (Fig. 6). Because the ability of R2 to co-assemble with microtubules was greatly enhanced by adding the upstream IBR domain (Fig. 2, R2 versus IBR-R2), we tested the IBR-R2/C431F construct and found that it co-assembled with microtubules much better than R2/C431F did (Fig. 6). The C431F mutant on the backbone of full-length parkin strongly co-assembled with microtubules (Fig. 6, last panel). These results suggest that none of the three PD-linked mutations disrupts the strong association between parkin and microtubules, because each of these point mutations would at most affect only one of the three microtubule-binding domains.

**PD-linked Mutations Do Not Affect the Ability of Parkin to Attenuate Colchicine-induced Microtubule Depolymerization**—Because the three PD-linked mutations did not disrupt the binding between parkin and microtubules, they should not significantly affect the ability of parkin to stabilize microtubules against colchicine-induced depolymerization. To test this, COS7 cells were transfected with wild-type or mutant parkin and treated without or with colchicine (1 μM) for 12 h. We co-stained fixed cultures with anti-FLAG (red) and anti-α-tubulin (green) to compare microtubule networks in transfected versus untransfected cells. Almost no microtubule was visible after colchicine treatment in untransfected cells (Fig. 4, A versus B). In many cells transfected with wild-type parkin or its PD-linked mutants (K161N, T240R, and C431F), microtubules were still quite visible after the colchicine treatment. After counting at least 200 transfected cells (for each condition in Fig. 7, C–H) and 500 untransfected cells (for each condition in Fig. 7, A and B) from four coverslips in separate experiments for each construct, we found that parkin or its mutants significantly increased the percentage of cells with at least one visible microtubule after colchicine treatment, in comparison to untransfected cells (p < 0.001).

To further substantiate these results, we measured the amount of free tubulin in HEK293T cells transfected with parkin or its mutants and treated without or with 1 μM colchicine for 40 min. Expression of wild-type or mutant parkin greatly reduced the amount of free tubulin induced by colchicine treatment (Fig. 7J, upper panel). Quantification of results from three different experiments showed that the amount of free tubulin after colchicine treatment in cells transfected with WT (157 ± 12% of untransfected, untreated controls, p < 0.01),...
Three Domains of Parkin Bind to and Stabilize Microtubules

Our previous study has demonstrated that parkin binds to microtubules with very high affinity; the interaction cannot be disrupted even in the presence of 2 M NaCl (11). The goal of the present study is to understand the molecular mechanism of this strong binding. Our results identified three separate domains of parkin, Linker, RING1, and RING2, which provided strong, independent binding to both tubulin and microtubules. The other two domains of parkin, Ubl and IBR, exhibited no significant interaction with tubulin or microtubules. Thus, the full-length parkin interacts with tubulin heterodimers and microtubules through three of the five functional domains, which may explain why parkin binds to tubulin and microtubules so tightly.

This strong interaction means that there is very little chance for parkin to separate from α/β-tubulin heterodimers and microtubules (i.e. polymerized tubulin heterodimers). In fact, we were not able to separate parkin from microtubules with 3.8 M NaCl (Fig. 3A) or 0.5 M urea (Fig. 3B). The binding between parkin and microtubules did not rely on taxol, because parkin strongly co-assembled with microtubules in temperature-mediated microtubule assembly assays in the absence of taxol (data not shown). Furthermore, parkin did not dissociate from microtubules in MAP dissociation buffer containing high concentrations of NaCl, but no taxol (Figs. 2, 3A, and 6). The strong association between parkin and tubulin heterodimers led to their co-purification in ion-exchange chromatography (Fig. 3C) and gel-filtration chromatography (data not shown). We actually found parkin by Western blot analysis of highly purified bovine tubulin (>99% purity) from a widely used commercial source (Fig. 3D). It is difficult for us to determine the relative amount of parkin in this tubulin preparation, because both parkin and tubulin migrated very closely on SDS-PAGE. Even with two-dimensional gel electrophoresis, it is unlikely to separate tubulin and parkin, because the first dimension for isoelectric focusing is done in native condition, in which parkin and tubulin would be in a complex. In any case, these results confirm the tight binding of parkin to tubulin and microtubules and suggest that parkin is very likely to be always associated with tubulin or microtubules in the cell under the normal situation.

Such inference is corroborated by our previous study, which has shown that taxol treatment of cells shifts parkin from the soluble fraction to the pellet fraction enriched with bundled microtubules (15). Consistent with this idea, we found in the present study that overexpression of parkin or any one of its tubulin/microtubule-binding domains significantly stabilized microtubules against colchicine-induced depolymerization (Fig. 4). Thus, one of the physiological consequences of a tight binding between parkin and microtubules seems to be the stabilization of microtubule networks in the cell. This may have many implications, because microtubules play essential roles in diverse cellular functions, such as intracellular transport, structural support, motility, etc. However, the ability of parkin to stabilize microtubules against colchicine-induced depolymerization was independent of its E3 ligase activity. We tested three PD-linked

FIG. 7. PD-linked mutations did not abrogate the microtubule-stabilizing effect of parkin against colchicine. A–H, COS-7 cells were transfected with FLAG-tagged wild-type parkin (A and B) or its PD-linked mutants K161N (C and D), T240R (E and F), or C431F (G and H). After treatment with vehicle control (A, C, E, and G) or 1 μM colchicine (B, D, F, and H) for 12 h, cells were co-stained with anti-FLAG (red) and anti-α-tubulin (green). Each of the four constructs greatly attenuated colchicine-induced microtubule depolymerization. Bar, 10 μm. J, percentages of cells with at least one obvious microtubule after colchicine treatment were calculated for all the constructs used in A–H. At least 200 transfected cells (for each condition in C–H) and 500 untransfected cells (for each condition in A and B) were counted from four coverslips in separate experiments for each construct. *, p < 0.001 versus untransfected controls. No significant differences were found between parkin and its mutants (p > 0.1). J, HEK293T cells were transfected without or with various FLAG-tagged parkin constructs and treated without or with colchicine (1 μM) for 40 min. Free tubulin was extracted from the cells and analyzed by Western blotting with anti-α-tubulin (upper panel). Expression of wild-type parkin or its mutants significantly reduced colchicine-induced microtubule depolymerization. Total cell lysates were blotted with anti-FLAG to show expression levels of FLAG-tagged parkin constructs (lower panel).
point mutations of parkin, which abrogate its E3 ligase activity, toward many substrates (6–12). None of these mutations significantly disrupted the binding of parkin to tubulin (Fig. 5) and microtubules (Fig. 6), nor did they affect the ability of parkin to attenuate colchicine-induced microtubule depolymerization (Fig. 7). These results suggest that the binding of parkin to tubulin and microtubules serves to anchor this E3 ligase; its enzymatic activity does not affect the anchorage.

This idea is consistent with our previous results that parkin binds to microtubules and to ubiquitinate misfolded transmembrane proteins. The combination of the two independent properties in parkin seems to make it uniquely suited to protect against these PD toxins.

DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY

REFERENCES

1. de Rijck, M. C., Breiter, M. M., Graveland, G. A., Ott, A., Grobbeke, D. E., van der Meer, P. G., and Hofman, A. (1995) Neurology 45, 2143–2146
2. Glazov, C. W., and Tatsou, W. G. (1999) Annu. Rev. Neurosci. 22, 123–144
3. Dekker, M. C., Bonifati, V., and van Duijn, C. M. (2003) Brain 126, 1722–1733
4. Shen, J. (2004) Neurouron 44, 575–577
5. Feng, J. (2003) Curr. Neuropharmacol. 1, 301–313
6. Zhang, Y., Gao, J., Chang, K. K., Huang, H., Dawson, V. L., and Dawson, T. M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 13554–13559
7. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., and Takahashi, R. (2001) Cell 105, 891–902
8. Shimohara, H., Schlossmacher, M. G., Hattori, N., Froehnich, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., and Selkoe, D. J. (2001) Science 293, 263–269
9. Chung, K. K., Zhang, Y., Lim, K. L., Tanaka, Y., Huang, H., Gao, J., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2001) Nat. Med. 7, 1144–1150
10. Staropoli, J. F., McDermott, C., Martinat, C., Schulman, B., Demireva, E., and Abeliovich, A. (2003) Neuron 37, 735–740
11. Ren, Y., Zhao, J. H., and Feng, J. (2003) J. Neurosci. 23, 3316–3324
12. Jiang, H., Jiang, Q., and Feng, J. (2004) J. Biol. Chem. 279, 54380–54386
13. Galloway, P. G., Mulivihill, P., and Perry, G. (1992) Am. J. Pathol. 140, 819–822
14. Leryt, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezei, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., Wilkinson, K. D., and Polymeropoulos, M. H. (1996) Nature 385, 451–456
15. Zhao, J., Ren, Y., Jiang, Q., and Feng, J. (2003) J. Cell Sci. 116, 4011–4019
16. Arley, H. C., Scott, G. B., Rose, S. A., Tan, N. G., Markham, A. F., and Robinson, P. A. (2003) Mol. Cell Biol. 14, 4541–4556
17. Cappelletti, G., Mazzanti, G., and Maci, R. (1999) J. Neurosci. Res. 56, 28–35
18. Cappelletti, G., Pedrotti, B., Cappelletti, G., Maci, M., and Maci, R. (2001) Cell Biol. Int. 25, 981–984
19. Brinkley, B. R., Barham, S. S., Barranco, S. C., and Fuller, G. M. (1974) Exp. Cell Res. 85, 41–46
20. Marshall, L. E., and Himes, R. H. (1978) Biochem. Biophys. Acta 543, 590–594
21. Drubin, D., Kobayashi, S., Kellogg, D., and Kirschner, M. W. (1988) J. Cell Biol. 106, 1583–1591
22. Cleveland, D. W. (1989) Curr. Opin. Cell Biol. 1, 10–14
23. Kapito, R. R. (2000) Trends Cell Biol. 10, 524–530
24. Joshi, H. C., and Cleveland, D. W. (1989) J. Cell Biol. 109, 663–673
25. Imai, Y., Soda, M., Murakami, T., Shoji, M., Abe, K., and Takahashi, R. (2003) J. Biol. Chem. 278, 51901–51910
26. Hayn, D. P., Soles, D. R., Nguyen, D., and Pule, S. M. (2003) Hum. Mol. Genet. 12, 2587–2597
27. Hampton, R. Y. (2002) Curr. Opin. Cell Biol. 14, 476–482
28. Tsunomaki, M., Chen, L. B., and Fujigawa, K. (1996) J. Cell Biol. 103, 1557–1568
29. Waterman-Storer, C. M., and Salmon, E. D. (1998) Curr. Biol. 8, 798–806
30. Cole, N. B., and Lippincott-Schwartz, J. (1995) Science 268, 1722–1733
31. Holstein, T. A., Loewen, C. E., and Storm, T. H. (1996) Science 278, 448–451
32. Barrios, A., and Morais, C. T. (1999) J. Biol. Chem. 274, 16188–16197
33. Kushnerava, Y., Murphy, A. N., and Andrevey, A. (2002) Biochem. J. 368, 543–553